Profit up 30.2% Hypermarcas in 4th tri, with smaller financial expenses

The company of medicines and consumer products had more than high Hypermarcas 30 percent in its net profit in the fourth quarter compared with the same period in 2013, driven by the reduction of net financial expenses.
The net profit amounted to 71.5 million reais from October to December, advancement of 30.2 percent in comparison with the same period of the previous year. The analysts ' average ears by Reuters anticipated high of 65.8 percent of net income.
The free cash flow was 100.7 percent advance in the fourth quarter, while net financial expenses fell 46.3 percent to 111 million reais, with better protection of the company's currency exposure.
Net revenues in the fourth quarter was 1.3 billion reais, up 16.3 percent year on year. This indicator was elevated by the advancement of 18 percent of revenues of the pharmaceutical division, and 14.5 percent of the consumer division in the quarter.
According to the company, the Consumer Division's revenues were benefited by lower pricing policy in particular for selected categories of high volume. Already the pharmaceutical division grew with the strong demand for products, particularly for the compressed version of Addera D3 (vitamin D), which was exceeding demand 41.7 million reais in 12 months.
The gross margin of the pharmaceutical division fell 0.2 percentage point in the quarter compared to the previous year, to 76.8 percent, while this indicator of consumer division fell six percentage points due to promotions strategy in this segment.
Adjusted Ebitda in the quarter was $ 273.2 million reais, up 8.4 percent.
In the year, had net profits of Hypermarcas 402.7 million reais, up 56.9 percent, reaching their target of Ebitda (stands for earnings before interest, taxes, depreciation and amortization) adjusted to 1.1 billion reais in 2014, which was discharged of 10.4 percent.
For 2015, Hypermarcas sees a growth of adjusted Ebitda. The company announced on Friday that estimates the indicator at about 1.2 billion dollars in the period.
The adjusted Ebitda margin climbed 0.1 percentage point on the same basis of comparison.